Fedratinib and Olaparib Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. In a drug interaction study with 57 patients, olaparib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.4- and 2.7-fold, respectively, during coadministration with the potent CYP450 3A4 inhibitor itraconazole. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that a moderate inhibitor (fluconazole) may increase olaparib Cmax by 1.1-fold and AUC by 2-fold. No data are available for use with other, less potent inhibitors. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort. MANAGEMENT: Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected. References "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. In a drug interaction study with 57 patients, olaparib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.4- and 2.7-fold, respectively, during coadministration with the potent CYP450 3A4 inhibitor itraconazole. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that a moderate inhibitor (fluconazole) may increase olaparib Cmax by 1.1-fold and AUC by 2-fold. No data are available for use with other, less potent inhibitors. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.

MANAGEMENT: Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected.

Fedratinib

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

What is Fedratinib?

Olaparib Tablets

Generic Name: olaparib

Brand name: Lynparza

Synonyms: Olaparib

What is Olaparib Tablets?